Although numerous biotech companies are developing gene therapies to correct eyesight, these approaches largely require the affected cells to remain intact — while many forms of vision loss are caused by dead or dying cells. That’s why a new startup is betting that advances in stem cell biology will enable treatments that restore vision by replacing or regenerating vital tissues lost to disease.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters